BMS 181174

Drug Profile

BMS 181174

Alternative Names: BMY 25067

Latest Information Update: 25 Jan 2000

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Cytostatic antibiotics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Gastrointestinal cancer; Lung cancer; Ovarian cancer

Most Recent Events

  • 25 Jan 2000 A clinical study has been added to the pharmacokinetics and adverse events sections
  • 10 Dec 1999 Discontinued-II for Ovarian cancer in USA (IV)
  • 10 Dec 1999 Discontinued-II for Lung cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top